CHA sent a comment letter to the FDA on draft guidance that recommends how and when manufacturers provide additional information in drug shortage notifications to the agency. Our letter urges the FDA to address the specific challenges facing the pediatric drug supply chain through transparency requirements, developing proactive shortage mitigation plans, and ensuring an accounting of pediatric drugs on the FDA drug shortages list.
CHA Submits Comments on FDA Drug Shortage Guidance
Children’s Hospital Association sends a comment letter to the FDA on draft drug shortage guidance to highlight the need for an efficient pediatric supply chain.
Related Content
3 Ways to Address Children's Greatest Health Threat
Monthly Vitals: Your Advocacy Update
CHA Applauds Actions Taken to Increase Access to Sickle Cell Disease Therapies
3 Ways to Address Children's Greatest Health Threat
Gun violence is the number one cause of death in children. What can children's hospitals do?
Dec. 18, 2024
Monthly Vitals: Your Advocacy Update
Learn about Children’s Hospital Association’s latest advocacy efforts and recent legislative impacts for children’s hospitals and health systems.
Dec. 05, 2024
CHA Applauds Actions Taken to Increase Access to Sickle Cell Disease Therapies
The Centers for Medicare and Medicaid Services (CMS) and the gene therapy manufacturers announce new agreement.
Dec. 05, 2024
